tiprankstipranks
Trending News
More News >
Orion Nutraceuticals, Inc. (TSE:ORI)
:ORI
Canadian Market

Orion Nutraceuticals (ORI) AI Stock Analysis

Compare
1 Followers

Top Page

TS

Orion Nutraceuticals

(ORI)

Rating:21Underperform
Price Target:
Orion Nutraceuticals exhibits significant financial instability, with no revenue and consistent losses. The technical analysis indicates a lack of momentum, while the negative P/E ratio and absence of dividends highlight valuation challenges. The lack of earnings call and corporate events data further limits insights into potential positive catalysts.

Orion Nutraceuticals (ORI) vs. iShares MSCI Canada ETF (EWC)

Orion Nutraceuticals Business Overview & Revenue Model

Company DescriptionOrion Nutraceuticals Inc. focuses on the drug for treating asthma and chronic obstructive pulmonary diseases in Canada. The company was formerly known as Cline Capital Corp. Orion Nutraceuticals Inc. was incorporated in 2017 and is headquartered in Vancouver, Canada.
How the Company Makes MoneyOrion Nutraceuticals generates revenue primarily through the sale of its nutraceutical products. The company's revenue model is based on direct sales to consumers through its online platform, as well as distribution partnerships with health stores and pharmacies. Key revenue streams include retail sales, subscription services for regular delivery of products, and wholesale agreements with healthcare providers. The company's earnings are bolstered by strategic partnerships with research institutions for product development and marketing collaborations with wellness influencers to expand its customer base.

Orion Nutraceuticals Financial Statement Overview

Summary
Orion Nutraceuticals is facing significant financial challenges, with no revenue generation and consistent losses impacting all aspects of its financial health. The balance sheet reflects high leverage and negative equity, while cash flow statements show persistent cash deficits, underscoring the need for strategic restructuring or new revenue streams to avoid further deterioration.
Income Statement
5
Very Negative
The company has consistently reported zero revenue across all periods, indicating no sales activity. Negative EBIT and EBITDA margins highlight significant operational inefficiencies. The net profit margin is also deeply negative, reflecting ongoing losses.
Balance Sheet
10
Very Negative
The balance sheet reveals negative stockholders' equity, implying financial instability and potential solvency issues. The company has a high debt-to-equity ratio, further increasing financial risk. The equity ratio is negative, emphasizing a precarious financial position.
Cash Flow
15
Very Negative
Operating and free cash flows are consistently negative, indicating insufficient cash from operations to cover expenses. The operating cash flow to net income ratio is negative, aligning with poor income performance. Financing activities occasionally provide cash inflow, but not enough to stabilize cash flow concerns.
Breakdown
TTMJun 2024Jun 2023Jun 2022Jun 2021Jun 2020
Income StatementTotal Revenue
0.000.000.000.000.000.00
Gross Profit
0.000.000.000.000.000.00
EBIT
-195.04K-316.36K-279.69K-282.39K-202.06K-699.95K
EBITDA
-528.58K-61.82K-279.69K2.06M-882.93K-386.24K
Net Income Common Stockholders
-528.07K-61.82K-279.69K-4.96M-1.23M-229.39K
Balance SheetCash, Cash Equivalents and Short-Term Investments
0.00193.46K3.99K9.43K280.19K501.29K
Total Assets
82.17K193.46K3.99K9.43K2.43M584.97K
Total Debt
0.0082.24K90.33K44.00K44.00K44.00K
Net Debt
0.00-111.22K86.34K34.57K-236.19K-457.29K
Total Liabilities
561.99K1.17M918.97K645.60K449.28K849.85K
Stockholders Equity
-479.82K-975.87K-914.05K-635.25K1.98M-263.96K
Cash FlowFree Cash Flow
-94.69K-56.94K-51.77K-82.92K-935.04K-47.98K
Operating Cash Flow
-94.69K-56.94K-51.77K-82.92K-935.04K-47.98K
Investing Cash Flow
0.00254.50K0.00-187.83K-2.40M0.00
Financing Cash Flow
-65.09K-8.10K46.33K0.003.11M544.00K

Orion Nutraceuticals Peers Comparison

Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
54
Neutral
$5.31B3.26-45.10%2.79%16.76%0.02%
TSACB
50
Neutral
$428.64M34.244.78%16.39%-98.10%
47
Neutral
$479.72M-122.10%-16.27%
TSORI
21
Underperform
C$797.31K6.34%-314.29%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
TSE:ORI
Orion Nutraceuticals
0.40
0.00
0.00%
TSE:WEED
Canopy Growth
2.20
-7.87
-78.15%
TSE:ACB
Aurora Cannabis
7.96
-0.14
-1.73%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.